With an upside potential of 56.13%, Cellebrite DI Ltd. (NASDAQ:CLBT) ranks among the stocks under $20 that will explode. Cellebrite (NASDAQ:CLBT) received a fresh vote of confidence from Wall Street, and the timing aligns with a quarter that gave ***** ysts plenty to ***** yze.
On May 27, 2026, DA Davidson initiated coverage of Cellebrite DI Ltd. (NASDAQ:CLBT) with a "Buy" rating and a $20 price target. The firm told investors in a research note that Cellebrite's total addressable market is large, growing, and likely understated. The ***** yst pointed to multiple drivers behind continued wallet share gains, along with the company's guided acceleration in organic annualized recurring revenue growth as a key reason for the bullish call.
That initiation came shortly after Cellebrite DI Ltd. (NASDAQ:CLBT)'s first-quarter 2026 results, where revenue climbed 19% year-over-year to $128.3 million and subscription revenue rose 23% to $117.9 million. Annual Recurring Revenue reached $493.0 million, up 21% from the prior year.
Needham had also weighed in earlier, on May 15, 2026, trimming its price target on Cellebrite DI Ltd. (NASDAQ:CLBT) to $15 from $18 while keeping a "Buy" rating. The firm said the company's first-quarter results had outperformed consensus estimates across the board, though it lowered its target to reflect a compressed valuation multiple in the stock.
Looking ahead, Cellebrite DI Ltd. (NASDAQ:CLBT) guided for full-year 2026 revenue between $565 million and $571 million, with ARR expected to land between $567 million and $573 million.
On May 27, 2026, DA Davidson initiated coverage of Cellebrite DI Ltd. (NASDAQ:CLBT) with a "Buy" rating and a $20 price target. The firm told investors in a research note that Cellebrite's total addressable market is large, growing, and likely understated. The ***** yst pointed to multiple drivers behind continued wallet share gains, along with the company's guided acceleration in organic annualized recurring revenue growth as a key reason for the bullish call.
That initiation came shortly after Cellebrite DI Ltd. (NASDAQ:CLBT)'s first-quarter 2026 results, where revenue climbed 19% year-over-year to $128.3 million and subscription revenue rose 23% to $117.9 million. Annual Recurring Revenue reached $493.0 million, up 21% from the prior year.
Needham had also weighed in earlier, on May 15, 2026, trimming its price target on Cellebrite DI Ltd. (NASDAQ:CLBT) to $15 from $18 while keeping a "Buy" rating. The firm said the company's first-quarter results had outperformed consensus estimates across the board, though it lowered its target to reflect a compressed valuation multiple in the stock.
Looking ahead, Cellebrite DI Ltd. (NASDAQ:CLBT) guided for full-year 2026 revenue between $565 million and $571 million, with ARR expected to land between $567 million and $573 million.
5 months ago
